Loading...
Please wait, while we are loading the content...
Similar Documents
The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model.
| Content Provider | Europe PMC |
|---|---|
| Author | Jae, Hwan Jun Chung, Jin Wook Park, Hee Sun Lee, Min Jong Lee, Ki Chang Kim, Hyo-Cheol Yoon, Jung Hwan Chung, Hesson Park, Jae Hyung |
| Copyright Year | 2009 |
| Abstract | ObjectiveThe purpose of this study was to compare the antitumor effect and hepatotoxicity of an intraarterial delivery of low-dose and high-dose 3-bromopyruvate (3-BrPA) and those of a conventional Lipiodol-doxorubicin emulsion in a rabbit VX2 hepatoma model.Materials and MethodsThis experiment was approved by the animal care committee at our institution. VX2 carcinoma was implanted in the livers of 36 rabbits. Transcatheter intraarterial administration was performed using low dose 3-BrPA (25 mL in a 1 mM concentration, n = 10), high dose 3-BrPA (25 mL in a 5 mM concentration, n = 10) and Lipiodol-doxorubicin emulsion (1.6 mg doxorubicin/ 0.4 mL Lipiodol, n = 10), and six rabbits were treated with normal saline alone as a control group. One week later, the proportion of tumor necrosis was calculated based on histopathologic examination. The hepatotoxicity was evaluated by biochemical analysis. The differences between these groups were statistically assessed with using Mann-Whitney U tests and Kruskal-Wallis tests.ResultsThe tumor necrosis rate was significantly higher in the high dose group (93% ± 7.6 [mean ± SD]) than that in the control group (48% ± 21.7) (p = 0.0002), but the tumor necrosis rate was not significantly higher in the low dose group (62% ± 20.0) (p = 0.2780). However, the tumor necrosis rate of the high dose group was significantly lower than that of the Lipiodol-doxorubicin treatment group (99% ± 2.7) (p = 0.0015). The hepatotoxicity observed in the 3-BrPA groups was comparable to that of the Lipiodol-doxorubicin group.ConclusionEven though intraarterial delivery of 3-BrPA shows a dose-related antitumor effect, single session treatment seems to have limited efficacy when compared with the conventional method. |
| ISSN | 12296929 |
| Journal | Korean Journal of Radiology |
| Volume Number | 10 |
| PubMed Central reference number | PMC2770822 |
| Issue Number | 6 |
| PubMed reference number | 19885316 |
| e-ISSN | 20058330 |
| DOI | 10.3348/kjr.2009.10.6.596 |
| Language | English |
| Publisher | The Korean Society of Radiology |
| Publisher Date | 2009-11-01 |
| Access Restriction | Open |
| Rights License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2009 The Korean Society of Radiology |
| Subject Keyword | Hepatocellular carcinoma 3-Bromopyruvate Hexokinase II inhibitor Intraarterial chemotherapy VX2 carcinoma |
| Content Type | Text |
| Resource Type | Article |
| Subject | Radiology, Nuclear Medicine and Imaging |
